Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison

P Moreau; B Hebraud; T Facon; X Leleu; C Hulin; M Hashim; Y Hu; D Caillot; L Benboubker; S Zweegman; M Merz; K Weisel; H Salwender; EK Mai; H Goldschmidt; U Bertsch; V Vanquickelberghe; T Kampfenkel; CD Boer; S Krotneva; I Proskorovsky; J He; A Lam; C Lee; S Cote; Pieter Sonneveld

doi:10.2217/imt-2020-0266

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison

P Moreau, B Hebraud, T Facon, X Leleu, C Hulin, M Hashim, Y Hu, D Caillot, L Benboubker, S Zweegman, M Merz, K Weisel, H Salwender, EK Mai, H Goldschmidt, U Bertsch, V Vanquickelberghe, T Kampfenkel, CD Boer, S KrotnevaI Proskorovsky, J He, A Lam, C Lee, S Cote, Pieter Sonneveld

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

Original language	English
Pages (from-to)	143-154
Number of pages	12
Journal	Immunotherapy
Volume	13
Issue number	2
DOIs	https://doi.org/10.2217/imt-2020-0266
Publication status	Published - Feb 2021

Research programs

EMC OR-01

Access to Document

10.2217/imt-2020-0266

Cite this

Moreau, P., Hebraud, B., Facon, T., Leleu, X., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., Merz, M., Weisel, K., Salwender, H., Mai, EK., Goldschmidt, H., Bertsch, U., Vanquickelberghe, V., Kampfenkel, T., Boer, CD., ... Sonneveld, P. (2021). Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison. Immunotherapy, 13(2), 143-154. https://doi.org/10.2217/imt-2020-0266

@article{352756c38585452f957d1b3d131b46e9,

title = "Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison",

abstract = "Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.",

author = "P Moreau and B Hebraud and T Facon and X Leleu and C Hulin and M Hashim and Y Hu and D Caillot and L Benboubker and S Zweegman and M Merz and K Weisel and H Salwender and EK Mai and H Goldschmidt and U Bertsch and V Vanquickelberghe and T Kampfenkel and CD Boer and S Krotneva and I Proskorovsky and J He and A Lam and C Lee and S Cote and Pieter Sonneveld",

year = "2021",

month = feb,

doi = "10.2217/imt-2020-0266",

language = "English",

volume = "13",

pages = "143--154",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor & Francis Ltd",

number = "2",

}

Moreau, P, Hebraud, B, Facon, T, Leleu, X, Hulin, C, Hashim, M, Hu, Y, Caillot, D, Benboubker, L, Zweegman, S, Merz, M, Weisel, K, Salwender, H, Mai, EK, Goldschmidt, H, Bertsch, U, Vanquickelberghe, V, Kampfenkel, T, Boer, CD, Krotneva, S, Proskorovsky, I, He, J, Lam, A, Lee, C, Cote, S & Sonneveld, P 2021, 'Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison', Immunotherapy, vol. 13, no. 2, pp. 143-154. https://doi.org/10.2217/imt-2020-0266

TY - JOUR

T1 - Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison

AU - Moreau, P

AU - Hebraud, B

AU - Facon, T

AU - Leleu, X

AU - Hulin, C

AU - Hashim, M

AU - Hu, Y

AU - Caillot, D

AU - Benboubker, L

AU - Zweegman, S

AU - Merz, M

AU - Weisel, K

AU - Salwender, H

AU - Mai, EK

AU - Goldschmidt, H

AU - Bertsch, U

AU - Vanquickelberghe, V

AU - Kampfenkel, T

AU - Boer, CD

AU - Krotneva, S

AU - Proskorovsky, I

AU - He, J

AU - Lam, A

AU - Lee, C

AU - Cote, S

AU - Sonneveld, Pieter

PY - 2021/2

Y1 - 2021/2

N2 - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

AB - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=85098178835&partnerID=8YFLogxK

U2 - 10.2217/imt-2020-0266

DO - 10.2217/imt-2020-0266

M3 - Article

SN - 1750-743X

VL - 13

SP - 143

EP - 154

JO - Immunotherapy

JF - Immunotherapy

IS - 2

ER -

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison

Abstract

Research programs

Access to Document

Other files and links

Fingerprint

Cite this